Osteoarthritis year in review 2023: Imaging
- PMID: 37879600
- DOI: 10.1016/j.joca.2023.10.005
Osteoarthritis year in review 2023: Imaging
Abstract
Purpose: This narrative review summarizes the original research in the field of in vivo osteoarthritis (OA) imaging between 1 January 2022 and 1 April 2023.
Methods: A PubMed search was conducted using the following several terms pertaining to OA imaging, including but not limited to "Osteoarthritis / OA", "Magnetic resonance imaging / MRI", "X-ray" "Computed tomography / CT", "artificial intelligence /AI", "deep learning", "machine learning". This review is organized by topics including the anatomical structure of interest and modality, AI, challenges of OA imaging in the context of clinical trials, and imaging biomarkers in clinical trials and interventional studies. Ex vivo and animal studies were excluded from this review.
Results: Two hundred and forty-nine publications were relevant to in vivo human OA imaging. Among the articles included, the knee joint (61%) and MRI (42%) were the predominant anatomical area and imaging modalities studied. Marked heterogeneity of structural tissue damage in OA knees was reported, a finding of potential relevance to clinical trial inclusion. The use of AI continues to rise rapidly to be applied in various aspect of OA imaging research but a lack of generalizability beyond highly standardized datasets limit interpretation and wide-spread application. No pharmacologic clinical trials using imaging data as outcome measures have been published in the period of interest.
Conclusions: Recent advances in OA imaging continue to heavily weigh on the use of AI. MRI remains the most important modality with a growing role in outcome prediction and classification.
Keywords: Artificial intelligence; Imaging; Osteoarthritis; Review.
Copyright © 2023. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest AG has received consultancies fees from Pfizer, Novartis, Coval, Medipost, ICM, TrialSpark and TissueGene and is shareholder of Boston Imaging Core Lab (BICL), LLC a company providing image assessment services. FWR is shareholder of BICL, LLC and has received consultancies fees from Calibr–California Institute of Biomedical Research and Grünenthal, GmbH.
Similar articles
-
Osteoarthritis year in review 2021: imaging.Osteoarthritis Cartilage. 2022 Feb;30(2):226-236. doi: 10.1016/j.joca.2021.11.012. Epub 2021 Nov 24. Osteoarthritis Cartilage. 2022. PMID: 34838670 Review.
-
Osteoarthritis year in review 2019: imaging.Osteoarthritis Cartilage. 2020 Mar;28(3):285-295. doi: 10.1016/j.joca.2019.11.009. Epub 2019 Dec 23. Osteoarthritis Cartilage. 2020. PMID: 31877380 Review.
-
Osteoarthritis year in review 2022: imaging.Osteoarthritis Cartilage. 2023 Aug;31(8):1003-1011. doi: 10.1016/j.joca.2023.03.005. Epub 2023 Mar 15. Osteoarthritis Cartilage. 2023. PMID: 36924919 Review.
-
Osteoarthritis year in review 2016: imaging.Osteoarthritis Cartilage. 2017 Feb;25(2):216-226. doi: 10.1016/j.joca.2016.12.009. Epub 2016 Dec 10. Osteoarthritis Cartilage. 2017. PMID: 27965137 Review.
-
Osteoarthritis year in review 2018: imaging.Osteoarthritis Cartilage. 2019 Mar;27(3):401-411. doi: 10.1016/j.joca.2018.12.009. Epub 2018 Dec 25. Osteoarthritis Cartilage. 2019. PMID: 30590194 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous